Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
about
Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysisAngiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical IntegrationComparison of risk factors and outcomes of gestational hypertension and pre-eclampsia.Revisiting the discriminatory accuracy of traditional risk factors in preeclampsia screening.Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).Platelet Count in First Trimester of Pregnancy as a Predictor of Perinatal Outcome.The use of ultrasound and other markers for early detection of preeclampsia.Serum-free placental growth factor isoform 1 at 11-13-week gestation: effects of maternal factors, mean arterial pressure, placental volume, and uterine artery pulsatility index.Competing risks model in screening for preeclampsia in twin pregnancies by maternal factors and biomarkers at 11-13 weeks' gestation.Impaired placentation in women with chronic hypertension that develop preeclampsia.Chronic hypertension and adverse pregnancy outcome: a cohort study.The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review.Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE).Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.Contingent screening for preterm pre-eclampsia.Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.Effect of metformin on maternal and neonatal outcomes in pregnant obese non-diabetic women: A meta-analysis.Maternal height and risk of hypertensive disorders in pregnancy.The association of first trimester uterine arteries Doppler velocimetry with different clinical phenotypes of hypertensive disorders of pregnancy: a longitudinal study.How do maternal factors impact preeclampsia prediction in Brazilian population?ASPRE trial: performance of screening for preterm pre-eclampsia.Competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations.Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.Hidden high rate of pre-eclampsia in twin compared with singleton pregnancy.Uterine artery pulsatility index in the first trimester: assessment of intersonographer and intersampling site measurement differences.Peripheral blood cell microRNA quantification during the first trimester predicts preeclampsia: Proof of concept.First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study.Early Detection of Preeclampsia Using Circulating Small non-coding RNA.Developing a new algorithm for first and second trimester preeclampsia screening in twin pregnancies.Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy.Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks' gestation.Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
P2860
Q26781800-01CF70EB-7764-4252-B485-8D9BB0A1023BQ26796661-506A7EB2-D3E3-4408-BDE2-AD98D8164C7DQ33596750-CD6C9328-BAEB-4E35-AC75-CE45A298E249Q33728661-E805594A-F1ED-45BA-B9FD-59681F605939Q37063617-8B6E0DB4-3D6E-437B-B699-F31640E2D7A2Q37658758-B093D004-FB00-4713-B3C7-F095DBF168CFQ37732185-498ED8E7-3405-4337-9DA8-F70600B68503Q38675971-0F3E76ED-0E99-4696-BC22-399370C9C482Q38757227-54FFF69D-DF70-40C1-AA68-B2F829A4D19AQ38805483-9224B820-3601-4B73-A119-CB635D3D5613Q38823697-3062DC4E-3B6C-43D2-991C-F297A499E914Q38844344-3B0A86DA-1C3B-4D37-8138-78B248C78F9FQ38906644-33EEE580-E4C7-4779-AC75-4D69460C65DCQ39025500-1D7D3F57-4404-4EFB-A69C-F8B9B969C691Q40149771-FF9AA463-B017-4D9E-9318-443F9AACC56CQ40235809-1B831AD6-6F8E-4B3D-A480-0D7F6E773D2BQ40323400-C0E4A9EF-0A8E-4069-A895-278C985D395BQ41574187-DF00F957-0AEB-4570-BA61-0D038EC8BAF5Q41593340-8CC19A37-7311-48D1-B2F0-3A074381F3DFQ46732357-D768761B-E530-473E-9534-01D614942A2EQ47175467-5C085B38-24E7-44D8-80E8-0DF079C67161Q47441698-639D7AD2-C3D8-413C-8EEC-BDB9FB0CC7A0Q47627161-BB58A132-B548-4631-A30B-987AAD40D7A2Q47752807-0C86E246-5E19-40E8-AAAE-245BF9AEE981Q47843646-BCF42B50-3C3A-48A7-A0E0-C6EF2CA3821FQ47929307-859B26BE-2E77-4E8D-9600-10815CB4510BQ48017621-F5CA956F-DE92-48E3-8197-499F9EF8AAFFQ48105879-043499D1-087D-4514-A1C8-ABAAE114468BQ48280474-6297FD89-B608-40C6-8328-463313CEE4B7Q48321056-6506ACC7-4905-4DA2-AD4E-CF008CC8CDA0Q50070190-68CBEE1A-E862-4ABD-8708-20709E051B97Q50318619-90B72221-0B16-40B6-B7BE-7A295109FA51Q50549921-254A5EFD-5740-4330-8BED-F884DDE2EF20Q50579452-C9725F9F-3733-4A5E-95BF-9D58FC21873EQ50693778-929D5D2A-292D-4805-A989-E30B1A95F9DBQ50744266-39C1EE5F-983E-4174-917F-10114F52E721Q50770314-46EB466B-953B-405B-9E88-6F9F7EAEFC0AQ50770396-91785DDA-6312-47AD-ACF1-F164E14EA18DQ50925614-F87443B4-8B57-483E-B7F3-90D3B3177146Q51458630-4F222B7D-8A14-4942-9823-1CBF0C756164
P2860
Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Competing risks model in scree ...... teristics and medical history.
@en
Competing risks model in scree ...... teristics and medical history.
@nl
type
label
Competing risks model in scree ...... teristics and medical history.
@en
Competing risks model in scree ...... teristics and medical history.
@nl
prefLabel
Competing risks model in scree ...... teristics and medical history.
@en
Competing risks model in scree ...... teristics and medical history.
@nl
P2093
P1476
Competing risks model in scree ...... cteristics and medical history
@en
P2093
David Wright
Kypros H Nicolaides
Ranjit Akolekar
P304
62.e1-62.e10
P356
10.1016/J.AJOG.2015.02.018
P407
P577
2015-02-25T00:00:00Z